[1]Amett FC,Edworthy SM, Bloch DA,et al.The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis[J].Arthritis Rheum,1988,31(3):315324.
[2]Fransen J, Riel PL.The Disease Activity Score and the EULAR response criteria [J].Clin Exp Rheumatol,2005,23(5 Suppl 39):s9399.
[3]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002: 115119.
[4]Felson DT,Aderson J,Boers M,et al.American college of rheumatology preliminary definition of improvement in rheumatoid rthritis[J].Arthritis Rheum, 1995,38:727735.
[5]蒋明,David YU,林孝义,等.中华风湿病学[M].北京:华夏出版社,2004:771775.
[6]刘风云,刘喜德,陈滢.中医药诊治类风湿关节炎的临床及实验研究进展[J].中华中医药学刊,2008, 26 (8 ):17681770.
[7]Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis[J].Arthritis Rheum,2008,59(6): 762784.
[8]Aarvak T,Natvig JB. Cellcell interactions in synovitis Antigen Presenting cells and T cell interaction in rheumatoid arthritis[J]. Arthritis Res,2001,3(1):1317.
[9]Rho YH,Chung CP,Oeser A,et al.Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis[J].Arthritis Rheum,2009,61(11):15801585.